Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: A key role for CCL9 (MIP-1γ) in osteoclastogenesis in vivo and in vitro

Blood

Volumn 107, Issue 6, 2006, Pages 2262-2270

  Yang, Meiheng ^a   Mailhot, Geneviève ^a   MacKay, Carole A ^a   Mason Savas, April ^a   Aubin, Justin ^a   Odgren, Paul R ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b S7 242   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; COLONY STIMULATING FACTOR 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 9; MONOCYTE CHEMOTACTIC PROTEIN ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN ANTIBODY; RECOMBINANT COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; EXTRAMEDULLARY HEMATOPOIESIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO CULTURE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MICROARRAY; PROTEIN SYNTHESIS INHIBITION; RAT; RAT STRAIN;

EID: 33644773495     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3365     Document Type: Article

References (39)

1. Marks SC, Jr., Odgren PR. The structure and development of the skeleton. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology, Vol. 1 (2nd ed). New York, NY: Academic Press; 2002:3-15.
2. Whyte MP. Sclerosing bone disorders. In: Fauvus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (5th ed). Washington, D.C.: American Society for Bone and Mineral Research; 2003:449-466.
3. de Vernejoul MC, Benichou O. Human osteopetrosis and other sclerosing disorders: recent genetic developments. Calcif Tissue Int. 2001;69:1-6.
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
5. Moutier R, Toyama K, Cotton WR, Gaines JF. Three recessive genes for congenital osteopetrosis in the Norway rat. J Heredity. 1976;67:189-190.
6. Marks SC Jr. Osteopetrosis in the toothless (tl) rat: presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermates. Am J Anat. 1977;149:289-297.
7. Dobbins DE, Sood R, Hashiramoto A, Hansen CT, Wilder RL, Remmers EF. Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat. Biochem Biophys Res Commun. 2002;294:1114-1120.
8. Van Wesenbeeck L, Odgren PR, MacKay CA, et al. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A. 2002;99:14303-14308.
9. Sundquist KT, Cecchini MG, Marks SC Jr. Colony-stimulating factor-1 injections improve but do not cure skeletal sclerosis in osteopetrotic (op) mice. Bone. 1995;16:39-46.
10. Marks SC Jr, Wojtowicz A, Szperl M, et al. Administration of colony stimulating factor-1 corrects some macrophage, dental, and skeletal defects in an osteopetrotic mutation (toothless, tl) in the rat. Bone. 1992;13:89-93.
11. Odgren PR, Popoff SN, Safadi FF, et al. The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF. Bone. 1999;25:175-181.
12. Yang M, Odgren PR. Molecular cloning and characterization of rat CCL9 (MIP-1gamma), the ortholog of mouse CCL9. Cytokine. 2005;31:94-102.
13. Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, Stashenko P. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol. 2004;173:2084-2090.
14. Lean JM, Murphy C, Fuller K, Chambers TJ. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem. 2002;87:386-393.
15. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res. 2003;18:1404-1418.
16. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res. 2003;44:79-84.
17. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 2004;19:2065-2077.
18. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003;102:311-319.
19. Warme BA, Epstein NJ, Trindade MC, et al. Proinflammatory mediator expression in a novel murine model of titanium-particle-induced intramedullary inflammation. J Biomed Mater Res B Appl Biomater. 2004;71:360-366.
20. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75-84.
21. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol. 2003;111:1185-1199.
22. Tran PB, Miller RJ. Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci. 2003;4:444-455.
23. Lindunger A, MacKay CA, Ek-Rylander B, Andersson G, Marks SC Jr. Histochemistry and biochemistry of tartrate-resistant acid phosphatase (TRAP) and tartrate-resistant acid adenosine triphosphatase (TrATPase) in bone, bone marrow and spleen: implications for osteoclast ontogeny. Bone Miner. 1990;10:109-119.
24. Odgren PR, Kim N, MacKay CA, Mason-Savas A, Choi Y, Marks SC Jr. The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue. Connect Tissue Res. 2003;44:264-271.
25. Wani MR, Fuller K, Kim NS, Choi Y, Chambers T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology. 1999;140:1927-1935.
26. Marks SC, Jr., Lundmark C, Wurtz T, et al. Facial development and type III collagen RNA expression: concurrent repression in the osteopetrotic (Toothless, tl) rat and rescue after treatment with colony-stimulating factor-1. Dev Dyn. 1999;215:117-125.
27. Odgren PR, Gartland A, MacKay CA. Production of high-activity digoxigenin-labeled riboprobes for in situ hybridization using the AmpliScribe™ T7 High Yield Transcription Kit. Epicentre Forum. 2003;10:6-7. Available online at http://www.epicentre.com/pdfforum/ 10_1ampliscribe.pdf.
28. Horton JE, Harper J, Harper E. Platelet factor 4 regulates osteoclastic bone resorption in vitro. Biochim Biophys Acta. 1980;630:459-462.
29. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood. 2000;95:1158-1166.
30. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock. 1995;4:155-160.
31. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:109-118.
32. Scheven BA, Milne JS, Hunter I, Robins SP. Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro. Biochem Biophys Res Commun. 1999;254:773-778.
33. Khan IA, Murphy PM, Casciotti L, et al. Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection. J Immunol. 2001;166:1930-1937.
34. Broxmeyer HE, Cooper S, Hangoc G, Gao JL, Murphy PM. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med. 1999;189:1987-1992.
35. Domachowske JB, Bonville CA, Gao JL, Murphy PM, Easton AJ, Rosenberg HF. The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol. 2000;165:2677-2682.
36. Grassi F, Piacentini A, Cristino S, et al. Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol. 2003;120:391-400.
37. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 chemokine upregulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol. 2004;199:244-251.
38. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33:28-37.
39. Votta BJ, White JR, Dodds RA, et al. CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol. 2000;183:196-207.